10 research outputs found
Data from: Patterns of relapse in extrapulmonary small cell carcinoma: retrospective analysis of outcomes from two cancer centres
Objectives: We conducted a retrospective review of patients with extrapulmonary small cell carcinomas (EPSCCs) to explore the distribution, treatments, patterns of relapse and outcomes by primary site. Setting: We have reviewed the outcomes of one of the largest data sets of consecutive patients with EPSCC identified from two major cancer centres. Participants: Consecutive patients with a histopathological diagnosis of EPSCC from the two institutions were retrospectively identified. Primary and secondary outcome measures: Outcomes were evaluated including stage at presentation, treatments given, sites of relapse, time to distant relapse, progression-free survival and overall survival (OS). Results: From a total 159 patients, 114 received first-line chemotherapy, 80.5% being platinum-based. Response rate was 48%. Commonest primary sites were genitourinary and gynaecological. 44% of patients presented with metastatic disease. 55.9% relapsed with liver the commonest site, whereas only 2.5% developed brain metastases. Median OS was 13.4 months for all patients, 7.6 months and 19.5 months for those with metastatic and non-metastatic disease, respectively. Gynaecological and head and neck patients had significantly better OS compared to gastrointestinal patients. Conclusions: EPSCCs demonstrate high response rates to chemotherapy and high rates of distant metastases. Primary sites may influence prognosis, and survival is optimal with a radical strategy. Brain metastases are rare and we therefore do not recommend prophylactic cranial irradiation
Table 2A: : Univariate Cox regression analysis for overall survival
Univariate Cox regression analysis for overall survival for patients with EPSCC
Figure 2b: Kaplan–Meier plot for overall survival (OS) for all patients, grouped by treatment intent.
Kaplan–Meier plot for overall survival (OS) for all patients, grouped by treatment intent
Figure 2a: Kaplan–Meier plot for overall survival (OS) for all patients, grouped by disease stage at diagnosis.
Kaplan–Meier plot for overall survival (OS) for all patients, grouped by disease stage at diagnosis
Table 1: Primary sites of extrapulmonary small cell carcinomas identified
Primary sites of EPSCC were grouped by organ system to aid analysi
Figure 1: Kaplan–Meier plot for progression-free survival (PFS) for all patients.
Kaplan–Meier plot for progression-free survival (PFS) for all patients